Kenvue Inc. (NYSE:KVUE) Stock Has Consensus Target Price of $19.33 According to Brokerages

Shares of Kenvue Inc. (NYSE:KVUE – Get Free Report) have earned an average rating of “Hold” from the ten brokerages that are covering the stock, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a hold rating. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $19.29.

Several equities research analysts have weighed in on KVUE shares. Wall Street Zen downgraded shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. UBS Group raised their price objective on Kenvue from $19.00 to $20.00 and gave the company a “neutral” rating in a research report on Monday, November 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Kenvue in a report on Friday, September 11th. HSBC lowered their target price on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Finally, Barclays raised their target price on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st.

Read Our Latest Stock Report on KVUE

Kenvue Price Performance

Shares of NYSE KVUE opened at $19.31 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.71 and a debt-to-equity ratio of 0.67. The firm has a market cap of $37.09 billion, a PE ratio of 21.94, a PEG ratio of 1.77 and a beta of 0.48. Kenvue has a 1-year low of $14.06 and a 1-year high of $20.13. The company has a fifty day moving average price of $18.41 and a 200 day moving average price of $18.24.

Kenvue (NYSE:KVUE – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.29. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.86 billion. During the same quarter in the prior year, the firm earned $0.28 EPS. The business’s revenue was up 3.2% on a year-over-year basis. Research analysts predict that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were paid a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date was Monday, September 21st. Kenvue’s dividend payout ratio is presently 95.45%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Johnson Financial Group Inc. purchased a new position in Kenvue during the second quarter worth $26,000. CoreCap Advisors LLC lifted its position in shares of Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares in the last quarter. GK Wealth Management LLC purchased a new stake in Kenvue in the third quarter valued at $27,000. Bell Investment Advisors Inc acquired a new stake in Kenvue in the second quarter valued at about $35,000. Finally, Keating Financial Advisory Services Inc. purchased a new stake in Kenvue during the 2nd quarter worth about $38,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

(Get Free Report)

Kenvue Inc is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products.

Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health.

The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.

Further Reading

Analyst Recommendations for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.